Rayno Life Science Biopharmaceutical Portfolio:Cubist(CBST $28.40) Up 12% On Teva Licensing Deal

get link Cubist settles with TEVA on generic Cubicin. Cubist was added to the Rayno Life Science Portfolio on 2/2/09 at a price of $22. Teva gets right to generic daptomycin MRSA product on 6/24/18 and admits Cubist patents are valid.

http://akinabridalcouture.com.au/product/karen-willis-holmes-belt-acc14/ Cubist Pharmaceuticals Settles CUBICIN Patent Litigation with Teva

order gabapentin online overnight Cubist Licenses Cubicin Antibiotic to Teva in Patent Suit Settlement – Bloomberg

No comments yet.

Leave a Reply